Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

SIGLEC6 x CD3 T cell engager for CLL

BC Staff
August 2, 2024 11:28 PM UTC

A bispecific antibody that simultaneously recruits T cells and blocks the cell surface receptor SIGLEC6 could help treat CLL by killing cancerous B cells, and preventing their homing the bone marrow and splenic tumor microenvironment.

In primary samples, SIGLEC6 protein expression was higher in B cells from CLL patients than B cells from healthy individuals, and expression of the SIGLEC6 ligand sTn was higher in bone marrow mesenchymal stromal cells from CLL patients than from healthy individuals. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Ohio State University